Skip to main content
. 2020 Oct 27;92(2):165–171. doi: 10.1136/jnnp-2020-323271

Figure 2.

Figure 2

Number of patients lost to follow-up. The number of patients lost to follow-up is shown for each assessment. The blue lines represent patients receiving edaravone and edaravone–edaravone; the yellow lines represent patients receiving placebo, and the blue dashed lines represent patients receiving placebo–edaravone. ALSFRS-R, Amyotrophic Lateral Sclerosis Functional Rating Scale—Revised; MiToS, Milano-Torino staging.